Sarepta Therapeutics (SRPT) Interest & Investment Income (2010 - 2022)

Sarepta Therapeutics' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $9.1 million for Q4 2022.

• In Q4 2022, Interest & Investment Income rose 9506.32% year-over-year to $9.1 million; the TTM figure through Dec 2022 stood at $16.5 million (up 4557.63% YoY), while the FY2023 annual figure was $36.3 million, up 119.9% from the prior year.
• Interest & Investment Income was $9.1 million for Q4 2022 at Sarepta Therapeutics, up from $4.8 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $9.1 million in Q4 2022 to a low of -$7.0 million in Q3 2018.
• Historically, Interest & Investment Income has averaged $403400.0 across 5 years, with a median of $160500.0 in 2021.
• The sharpest annual moves came in 2018 and 2022: Interest & Investment Income slumped 3886.96% in 2018, then surged 9506.32% in 2022.
• A 5-year view of Interest & Investment Income shows it stood at -$2.3 million in 2018, then surged by 164.04% to $1.5 million in 2019, then slumped by 95.2% to $71000.0 in 2020, then surged by 33.8% to $95000.0 in 2021, then soared by 9506.32% to $9.1 million in 2022.
• The last three Interest & Investment Income figures came in at $9.1 million (Q4 2022), $4.8 million (Q3 2022), and $2.4 million (Q2 2022), per Business Quant data.